glp 1 history Timeline of GLP-1 discovery and clinical development. (a) Key events in Reflections on the discovery GLP-1

In a Phase 2a substudy published in Nature Medicine, retatrutide at the 12mg dose reduced liver fat by an average of 82.4% from baseline at 24 weeks

Physics Reports

Emphasize whole, nutrient-dense foods like vegetables, fruits, lean proteins, and whole grains

In this study, participants using semaglutide had a lower risk for CVD-related events when compared with placebo.38 These results build on prior evidence that GLP-1s not only support blood sugar and weight management but also offer significant cardiovascular protection in high-risk populations.39 A 2021 systematic review published in Diabetes & Metabolic Syndrome: Clinical Research & Reviews examined six studies involving over 182,000 adults with T2DM to evaluate the cardioprotective effects of GLP-1s (primarily liraglutide and exenatide) taken in conjunction with blood pressure and cholesterol lowering medications.40 The findings showed consistent improvements in cardiac function, including increased left ventricular ejection fraction40 and reduced heart chamber volume, along with weight loss and improved myocardial blood flow

Similarly, although patients treated with exenatide or liraglutide may experience injection-site reactions and, rarely, localised transient urticaria, the skin has not traditionally been viewed as a site of incretin action

Over time, this combination may help reduce hunger between meals, improve portion control, and promote sustained energy levels